Li Watsek
Stock Analyst at Cantor Fitzgerald
(0)
# 4755
Out of 5,240 analysts
84
Total ratings
28.57%
Success rate
-22.74%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IDEAYA Biosciences | Reiterates: Overweight | n/a | n/a | n/a | 2 | Jan 13, 2025 | |
ALX Oncology Holding... | Reiterates: Overweight | n/a | n/a | n/a | 6 | Dec 18, 2024 | |
Kura Oncology | Reiterates: Overweight | n/a | n/a | n/a | 10 | Dec 9, 2024 | |
Affimed | Reiterates: Overweight | n/a | n/a | n/a | 7 | Nov 19, 2024 | |
Ascendis Pharma | Reiterates: Overweight | 170 170 | 135 | 25.93% | 15 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 20 | 6.58 | 203.95% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 | 0.98 | 206.12% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 220 | 4.2 | 5138.1% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 26 | n/a | n/a | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 5 | 1.33 | 275.94% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 38 | 0.2 | 18900% | 2 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 38 | 2.28 | 1566.67% | 1 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 69 | n/a | n/a | 2 | Aug 9, 2022 |